Aplastic anemia is rare — but when it strikes, it moves fast. It's a condition where the bone marrow stops producing enough blood cells, leaving the body without the tools it needs to fight infection, carry oxygen, or stop bleeding. For families facing this diagnosis, the treatment options and their implications can feel overwhelming. One of the most important of those options is a stem cell transplant — and cord blood is an increasingly significant source.
What Is Aplastic Anemia?
Aplastic anemia occurs when the immune system mistakenly attacks the stem cells in bone marrow — the cells responsible for producing red blood cells, white blood cells, and platelets. When bone marrow fails, the consequences are serious: severe anaemia, vulnerability to infection, and uncontrolled bleeding.
The condition can be acquired (triggered by autoimmune attack, viral infection, toxic exposure, or certain medications) or inherited, as in Fanconi anaemia — a genetic disorder that significantly increases aplastic anemia risk and is one of the most established indications for cord blood transplant.
💡 Aplastic anemia affects approximately 2 in every 1,000,000 people annually in the US, but the impact is disproportionately severe in children and young adults. Stem cell transplant — including from cord blood — is the only potentially curative treatment for severe cases.
Severity ranges from moderate to very severe. In severe and very severe aplastic anemia, without treatment, the five-year survival rate is below 20%. With appropriate treatment — including stem cell transplant — outcomes improve dramatically.
How Cord Blood Transplants Work for Aplastic Anemia
A haematopoietic stem cell transplant (HSCT) for aplastic anemia works by replacing the failed bone marrow with healthy donor stem cells that can rebuild the blood-producing system. The process involves conditioning (chemotherapy to suppress the immune system), infusion of cord blood stem cells intravenously, and engraftment — the process by which new stem cells establish themselves in the bone marrow and begin producing healthy blood cells over weeks to months.
A 2026 study in Annals of Medicne demonstrated that cord blood transplants achieved durable engraftment in paediatric aplastic anemia patients, with overall survival rates comparable to matched bone marrow transplants — while offering significantly greater donor availability, particularly for patients from ethnic minority backgrounds who face lower match rates in bone marrow registries.
A 2015 review in NIH further confirmed that advances in conditioning regimens and cord blood processing had meaningfully improved engraftment rates in aplastic anemia patients over the preceding decade, narrowing the historical gap between cord blood and matched unrelated donor bone marrow.
Why Cord Blood Has Specific Advantages for Aplastic Anemia
HLA matching flexibility. Cord blood stem cells are immunologically less mature than adult bone marrow cells, which means they can tolerate greater HLA mismatches without triggering severe graft-versus-host disease (GvHD). For patients who cannot find a perfectly matched bone marrow donor — which is especially common in non-European ethnic groups — cord blood significantly expands the pool of viable donors.
Speed of access. Finding a matched unrelated bone marrow donor can take months. A sibling's banked cord blood is immediately available — a critical advantage in severe aplastic anemia, where time matters.
Lower GvHD risk. Graft-versus-host disease, where donor immune cells attack the recipient's tissues, is a major complication of allogeneic transplants. Cord blood's immunological immaturity reduces — though does not eliminate — this risk compared to adult bone marrow.
Sibling matching. A matched sibling donor remains the gold standard for aplastic anemia transplants. If a sibling's cord blood was banked at birth, it represents the most accessible, fastest, and often best-matched source available. This is one of the strongest clinical arguments for banking a new baby's cord blood when an older sibling has a known haematological condition.
The Fanconi Anemia Connection
Fanconi anemia deserves particular mention. It is an inherited genetic disorder that causes progressive bone marrow failure and significantly increases aplastic anemia risk, typically presenting in childhood. Cord blood transplant from a matched sibling donor is the established treatment of choice.
For families with a known Fanconi anemia diagnosis in an existing child, the birth of a subsequent sibling represents a critical banking opportunity — if the new sibling is HLA-matched and Fanconi-negative, their cord blood may be the best treatment option available. Directed banking for this purpose is well-established and clinically recognised.
What This Means for Families Banking with AlphaCord
AlphaCord's AABB-accredited, FDA-registered storage is designed to meet clinical release standards — including for haematological transplant use. The 5-chamber bag preserves up to five treatment-ready units from a single cord blood collection, which is particularly relevant in conditions like aplastic anemia where treatment may require substantial cell volumes.
For families with a history of aplastic anemia, Fanconi anemia, or other bone marrow failure conditions, cord blood banking is not just a precaution — it's a clinically motivated decision with direct treatment implications. To understand the full landscape of what stem cells are and what cord blood banking covers, read our complete guide: What Are Stem Cells? A Complete Guide for Parents.
Frequently Asked Questions
Can cord blood cure aplastic anemia? A stem cell transplant — including from cord blood — is the only potentially curative treatment for severe aplastic anemia. Outcomes depend on factors including match quality, patient age, disease severity, and how quickly transplant occurs after diagnosis.
Does the cord blood donor need to be a sibling? A matched sibling is the preferred donor, as siblings have the highest likelihood of HLA compatibility. However, unrelated cord blood donors from public banks are also used when a matched sibling is unavailable. The advantage of private banking is immediate, certain access to a family member's sample.
How does cord blood compare to bone marrow for aplastic anemia? A matched sibling bone marrow donor remains the historical gold standard. Cord blood from a matched sibling is the next best option when a bone marrow harvest is not possible. For unrelated donors, cord blood outcomes have improved significantly and now approach matched unrelated bone marrow results in paediatric patients.
Don't Wait Until You Need It
Cord blood is collected once — at birth — and banked for a future that no one can fully predict. For conditions like aplastic anemia, having that sample available can be the difference between having options and not.
